

December 05, 2003

Suven board okays merger of subsidiary

THE board of directors of Suven Pharmaceuticals Ltd, at its meeting held on Thursday, approved a proposal to merge its wholly-owned subsidiary - Suven Synthesis Ltd - into the company.

In a communiqué to stock exchanges, the company said the decision was, however, subject to the approval of the Andhra Pradesh High Court, stock exchanges, banks, shareholders and creditors.

The company plans to convene an extraordinary general meeting of its shareholders on January 5 to obtain their approval for the scheme of arrangement. The Suven board has cleared a resolution to issue not exceeding 10-lakh equity shares, at a price not less than the price calculated as per SEBI guidelines on preferential offer basis, to foreign institutional investors /banks/bodies corporate/financial institutions or its nominees or affiliates.

The board has also approved a proposal to increase investment limit of FIIs up to 40 per cent. A proposal to subdivide equity shares into face value of Rs 2 each from the existing Rs 10 each was also approved, the company said. (Business Line)

Suven Life board decides to split shares

The board of directors of Suven Life Sciences Limited, formerly Suven Pharma, at its meeting decided to sub-divide the equity shares into face value of Rs 2 each from the present face value of Rs 10 each.

The company also proposed to offer equity shares not exceeding 10 lakhs, at a price as per the SEBI guidelines or higher, on preferential basis to foreign institutional investors, banks, corporate bodies, financial institutions besides the company's nominees or affiliates.

The company will seek the shareholders' nod for the above at the extra-ordinary general meeting (EGM) to be held on January 5, 2004.

The company will also seek the approval of shareholders to increase the FIIs investment limit upto 40 per cent of the paid-up capital, for enabling FIIs to acquire shares of the company.

The FIIs holding in the company was zero as on September 30. If the company places all the 10 lakh equity shares with the FIIs in the current round, their holding would go up to 18.51 per cent.

The company's board has approved the proposal to meger its 100 per cent subsidiary, Suven Synthesis Ltd, with the parent.

Suven Synthesis has an active pharmaceutical ingredients (APIs) manufacturing capacity on the outskirts of Hyderabad. The Rs 18-crore unit recently commenced trial runs. ([Business Standard](#))